Background LRFN4 is a pivotal molecule in the genesis and progression of cancer. Nevertheless, its function in Gastric Cancer (GC) and its correlation with glutamine catabolism remain elusive. Objective To explore the clinical significance and prognostic predictive value of LRFN4 in gastric cancer and to verify its impact on glutamine metabolism in gastric cancer cell lines through in-vitro cellular experiments. Methods Bioinformatics approaches were utilized to analyze the influence of LRFN4 on the clinical prognosis and other aspects of gastric cancer patients, by means of databases such as TCGA, GEPIA, and kmplot, along with R language software. Gastric cancer cell lines were employed to detect glutamine metabolic activity via glutamine uptake and glutaminase activity assays, CCK - 8 assay for cell proliferation, and flow cytometry for cell apoptosis, aiming to verify the biological functions of LRFN4 on gastric cancer cells. Results Differential analysis revealed that LRFN4 expression was markedly upregulated in gastric cancer tissues (P<0.05). Prognostic analysis indicated that both the overall survival and disease-free survival of gastric cancer patients in the high-expression group were lower than those in the low-expression group (P<0.05), suggesting that LRFN4 holds guiding significance for the prognosis of gastric cancer patients. LRFN4 may affect the occurrence and development of gastric cancer through signaling pathways like CELL CYCLE, promote cell proliferation (P<0.05), and inhibit cell apoptosis (P< 0.05) by influencing glutamine metabolism. Conclusion LRFN4 may be associated with the prognosis of gastric cancer patients by modulating glutamine metabolism, functioning as an oncogenic driver in gastric cancer cells, promoting tumor cell proliferation, and inhibiting cell apoptosis.